CARDIOVASCULAR
hamburger

Heart failure has devastating consequences in the United States and while the average age of patients is much higher, it can affect the lives of children and their families.  For many types of pediatric heart failure patients, receiving a heart transplant is the gold standard in care.  While waiting for a heart transplant, some children may require a left ventricular assist device (LVAD) to support their heart until a donor heart is available. In addition, children who are not current candidates for heart transplantation may receive an LVAD to allow the child to resume a sense of normal life.

“One of the most depressing aspects of heart failure is seeing your child not be able to do what had always come naturally. With the HeartMate 3™ LVAD, we have a chance to get back to living life on her terms."

- Katrina's Mom, Maria

Katrina with her mom Maria

Katrina with her mom Maria

What is an LVAD?

A left ventricular assist device (commonly known as an LVAD) is a small implantable pump attached to the heart.

An LVAD supports the pumping function of the heart and helps circulate oxygen-rich blood throughout the body for patients whose hearts are too weak to pump blood adequately on their own.

An LVAD can help patients breath more easily and feel less tired, as well as decrease fluid build-up and swelling. LVAD patients may also return to enjoyable activities with the advice of their doctor.

Drawing of a young pediatric heart failure girl wearing an LVAD.

Introducing the HeartMate 3 LVAD

The HeartMate 3 LVAD is one of the first FDA implantable continuous flow devices for pediatric patients.

The small, 2 inch in diameter HeartMate 3™ LVAD has been approved as a short-term therapy for adult patients with advanced heart failure since 2017 and was approved for long-term use in 2018. The HeartMate 3 was approved for use in pediatric patients in 2020, and is the latest innovation in LVAD therapy.

Please talk to your doctor to learn more about LVAD therapy and whether HeartMate 3™ LVAD is right for your family.

Advanced Cardiac Therapies Improving Outcomes Network (ACTION)

Abbott collaborated with the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) to advocate the importance of the HeartMate 3 LVAD as a life-saving resource for some of their most vulnerable patients.

Learn more about the ACTION Learning Network and explore additional resources.


About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 employees serve people in more than 160 countries.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions For Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications: The HeartMate 3™ Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

Contraindications: The HeartMate 3™ Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

Adverse Events: Adverse events that may be associated with the use of the HeartMate 3™ Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

MAT-2012542 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.